As per the research report, the size of the Asia Pacific PEGylated Proteins Market is valued at USD 168.94 million in 2022 and estimated to be growing at a CAGR of 12.50%, to reach USD 304.44 million by 2027 during the forecast period 2022 to 2027.
The market for PEGylated protein therapeutics is expected to develop significantly over the forecast period, owing to rising demand for PEGylation, an increase in the number of chronic diseases, and promising pipeline medications. Furthermore, PEGylated compounds also have various benefits, such as a longer half-life, decreased toxicity, lower immunogenicity, and increased proteolytic protection, contributing to the market's growth in the Asia Pacific region. In addition, biotechnology raised the number of lifestyle diseases and the growing demand for efficient therapies and innovations, promoting market growth.
The increased effectiveness of protein-based therapies in contrast to non-protein-based drugs and the increased protein stability are expected to propel the PEGylated proteins market forward in the upcoming years. In addition, PEGylated proteins provide a wide range of applications and benefits over standard therapy. Hence they are widely used. During the forecast period, the overall growth of the APAC PEGylated protein market is likely to be accelerated by ongoing clinical trials done by several pharmaceutical companies and increased demand for disease-specific new treatments.
Furthermore, increasing special designations from regulatory bodies is likely to help the market's overall growth. Furthermore, increased patient and healthcare professional awareness of the negative consequences of existing cancer treatments, such as chemotherapy & radiation therapy, is a significant reason for the rising popularity of alternative therapeutics such as pegylated peptide-based medications.
Drug development is a difficult and time-consuming procedure. Because drug development failures are so common, the chances of medicine being produced during the first trial are slim. The overall failure rate in drug development is roughly 96 percent, with clinical development failing at 90 percent. Pharmaceutical businesses face a variety of consequences resulting from an expensive medication failure, including site closures, job losses, and depleted research and development funds. As a result, setbacks in medication development and increased therapeutic drug recalls could stymie the PEGylated proteins market's expansion over the forecast period.
However, the limited operating revenue potential for research and development of targeted medicines by many pharmaceutical companies and the poor healthcare budgets in this developing country are expected to hamper the Asia Pacific Pegylated Protein market's expansion in the coming years.
This research report on the Asia Pacific Pegylated Proteins Market has been segmented and sub-segmented into the following categories:
By Protein Type:
By Application:
By Consumables:
By End-User:
By Country:
Geographically, Asia Pacific is expected to be the worldwide market's fastest expanding market due to the widespread use of PEGylated proteins in cancer, blood disorders, and chronic and autoimmune diseases that are likely to fuel market growth in this area.
The India Pegylated Proteins Market is expected to grow at a significant rate due to the vast population base, growth in healthcare infrastructure, and rapid rise in the frequency of chronic disease, and delivers lucrative opportunities for key players.
The China Pegylated Proteins Market is predicted to reach a decent CAGR during the forecast period and is the third-largest player in the market for PEGylated pharmaceuticals.
KEY MARKET PLAYERS
The Top companies leading in the APAC PEGylated Proteins Market profiled in the report are Laysan Bio, Ltd., Iris Biotech GmbH, Biomatrik Inc., Quanta BioDesign Ltd., Cealares GmbH, Creative PEGworks, Jenkem Technology USA Inc., NOF Corporation, Thermo Fisher Scientific Inc., and Merck Millipore.,
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Protein Type
5.1.1 Introduction
5.1.2 Interferons
5.1.3 Erythropoietin
5.1.4 mAbs
5.1.5 Y-o-Y Growth Analysis, By Protein Type
5.1.6 Market Attractiveness Analysis, By Protein Type
5.1.7 Market Share Analysis, By Protein Type
5.2 Consumables
5.2.1 Introduction
5.2.2 Reagents
5.2.3 PEGylation Kits
5.2.4 Y-o-Y Growth Analysis, By Consumables
5.2.5 Market Attractiveness Analysis, By Consumables
5.2.6 Market Share Analysis, By Consumables
5.3 Application
5.3.1 Introduction
5.3.2 Chronic Kidney Diseases
5.3.3 Cancer Treatment
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
5.4 End-Users
5.4.1 Introduction
5.4.2 Pharmaceuticals & Biotechnology Companies
5.4.3 CROs
5.4.4 Academic Research Institutes
5.4.5 Y-o-Y Growth Analysis, By End-Users
5.4.6 Market Attractiveness Analysis, By End-Users
5.4.7 Market Share Analysis, By End-Users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Protein Type
6.1.3.3 By Consumables
6.1.3.4 By Application
6.1.3.5 By End-Users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Protein Type
6.1.4.3 By Consumables
6.1.4.4 By Application
6.1.4.5 By End-Users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Protein Type
6.1.5.3 By Consumables
6.1.5.4 By Application
6.1.5.5 By End-Users
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Laysan Bio Ltd.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Iris Biotech GmbH
8.3 Biomatrik Inc.
8.4 Quanta BioDesign Ltd.
8.5 Cealares GmbH
8.6 Creative PEGworks
8.7 Jenkem Technology USA Inc.
8.8 NOF Corporation
8.9 Thermo Fisher Scientific Inc.
8.10 Merck Millipore
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
